Disc Medicine, Inc, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company’s Chief Technical Officer. Dr. Kaushik is an experienced biotech executive with significant expertise in chemistry, manufacturing, and controls (CMC) leadership across technical development, manufacturing and supply chain oversight for products in multiple modalities and therapeutic areas.
“Rahul’s experience is an ideal fit for Disc as we evolve into a late-stage development company,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “His depth of CMC expertise in multiple therapeutic modalities and track record of developing products through regulatory approval and commercialization will be fundamental assets as we continue to advance our pipeline. We are thrilled to welcome him to our leadership team.”
“I am excited to work with the talented team at Disc and build on their momentum established to date. It is a pivotal moment in the company’s history, with significant development milestones in the near term across all three clinical programs,” said Dr. Kaushik. “I am eager to contribute to Disc’s mission of providing meaningful, novel therapies to patients with high unmet medical need across diverse hematological conditions.”
Also Read: UPM Biomedicals Unveils FibGel™: World’s First Injectable Nanocellulose Hydrogel
Dr. Kaushik has more than 21 years of experience in pharmaceutical development, having held senior leadership positions at several top biotechnology companies. Most recently, he served on the executive team at FibroGen as Senior Vice President of Technical Operations, where he led process development, manufacturing and supply chain operations for all portfolio programs including BLA readiness for pamrevlumab and commercial manufacturing for Evrenzo® (roxadustat). Prior to joining FibroGen, Dr. Kaushik was the Executive Director and head of external manufacturing at Nektar Therapeutics, where he led CMC aspects including technology transfer, GMP manufacturing, process characterization and process validation of bempegaldesleukin, a PEGylated conjugate of IL-2. Prior to this, Dr. Kaushik spent over 15 years at Amgen, where he held a variety of leadership roles within CMC including formulation development, analytical development, process development, technology transfer, process characterization and PPQ oversight.
Across these experiences, Dr. Kaushik was an integral part of teams that enabled the pharmaceutical development and regulatory approval for Repatha (evolocumab), and Amgevita® (adalimumab-atto), contributed to CMC development of several agents into early and late-stage clinical trials, as well as provided scientific leadership for lifecycle management of commercial franchises ncluding Kyprolis® (carfilzomib), Neulasta (Pegfilgrastim) and Imlygic® (talimogene laherparepvac). He also led the team that created a state of the art, end-to-end pilot manufacturing facility to serve pipeline programs. Rahul graduated with an integrated bachelors plus master’s degree in Chemistry from I.I.T. Bombay in India as class valedictorian. He then obtained a full scholarship to pursue and complete his Ph.D. from Stanford University across the Chemistry and Biological Sciences departments, studying intracellular protein misfolding that was implicated in neurodegenerative disorders.
SOURCE: GlobeNewswire